Literature DB >> 1727721

Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney.

W R Mercer1, Z S Krozowski.   

Abstract

An 11 beta hydroxysteroid dehydrogenase (11 beta HSD) activity has been localized in the rat kidney by a histochemical technique which links steroid metabolism with the production of a color reaction. Oxidation of 11 beta-hydroxyandrostenedione was observed in cortical distal convoluted tubules and in medullary collecting ducts. Carbenoxolone abolished staining, no reaction was obtained with androstenedione hydroxylated at the 17 or 19 position, and oxidation of 11 beta-hydroxyandrostenedione was nicotinamide-adenine dinucleotide (NAD) dependent. These results demonstrate the presence of a dehydrogenase activity separate from the nicotinamide-adenine dinucleotide phosphate (NADP)-dependent 11 beta hydroxysteroid dehydrogenase recently purified and cloned from rat liver. We have named this activity 11 beta HSD2 to distinguish it from the NADP-dependent 11 beta HSD. Histological studies showed that 11 beta HSD2 activity does not correlate with the immunocytochemical localization of the previously defined 11 beta HSD enzyme, but rather the 11 beta HSD2 activity is localized in the distal tubules of the rat kidney. In this respect 11 beta HSD2 colocalizes with the mineralocorticoid receptor. No reaction product was obtained using cortisol or corticosterone as substrate with either NAD or NADP as cofactor. Furthermore incubation of tissue sections with 11 beta androstenedione in the presence of deoxycorticosterone completely inhibited cytochemical staining. We interpret these results as evidence of 20 reductase activity which uses the reduced cofactor at the expense of the color reaction. These results support the crucial role played by an 11 beta hydroxysteroid dehydrogenase in the local protection of type I receptors in mineralocorticoid selective tissues.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727721     DOI: 10.1210/endo.130.1.1727721

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 2.  Aldosterone in the brain.

Authors:  Joel C Geerling; Arthur D Loewy
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-04

Review 3.  Glucocorticoid and mineralocorticoid resistance.

Authors:  P A Komesaroff; M C Zennaro
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

4.  Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess.

Authors:  M I New; R C Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 5.  11 beta-Hydroxysteroid dehydrogenase: a relevant determinant of gluco- and mineralocorticoid-actions.

Authors:  F J Frey
Journal:  Clin Investig       Date:  1994-09

6.  11 beta-hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism.

Authors:  M W Voice; J R Seckl; C R Edwards; K E Chapman
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

7.  Mineralocorticoids, hypertension, and cardiac fibrosis.

Authors:  M Young; M Fullerton; R Dilley; J Funder
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.